Advertisement

U.S. Markets closed

S&P Futures
5,884.50
-2.50(-0.04%)
Dow Futures
43,496.00
-15.00(-0.03%)
Nasdaq Futures
20,358.25
-9.75(-0.05%)
Russell 2000 Futures
2,293.10
-4.60(-0.20%)
Crude Oil
71.02
+0.35(+0.50%)
Gold
2,712.90
+5.40(+0.20%)

NeuroBo Pharmaceuticals, Inc. (NRBO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

3.1600

+0.2000

(+6.76%)

At close: 04:00PM EDT

3.2800

+0.12

(+3.80%)

After hours:

07:09PM EDT

Loading interactive chart...

Zacks Small Cap Research
NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25…
By David Bautz, PhD NASDAQ:NRBO READ THE FULL NRBO RESEARCH REPORT On September 30, 2024, NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) announced positive topline results for the single ascending dose (SAD) Part 1 of the ongoing Phase 1 clinical trial of DA-1726 for the treatment of obesity. A total of 45 obese but otherwise healthy individuals were randomized in a double blind, 6:3 ratio to
PR Newswire
NeuroBo Pharmaceuticals to Participate in Investor Conferences in October
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that management will participate in the following investor conferences in October: